Navigation Links
Vaccine extends glioblastoma patients' survival in phase II trial
Date:10/6/2010

HOUSTON - A vaccine that turns the immune system against brain tumor cells bearing a genetic mutation that drives the most aggressive form of glioblastoma multiforme improved survival of patients in a phase II clinical trial, researchers at Duke University and The University of Texas MD Anderson Cancer Center reported today in the Journal of Clinical Oncology.

Eighteen newly diagnosed patients who were vaccinated after undergoing standard treatment - surgery followed by radiation and chemotherapy - had median overall survival of 26 months compared with 15 months for 17 patients in a control group who received standard treatment. Median survival for newly diagnosed patients with glioblastoma multiforme is 14.6 months.

Vaccinated patients also experienced a longer period before their disease progressed, 14.2 months, compared with 6.3 months for the control group. Side effects were limited mainly to irritation at the injection site.

"This promising targeted therapy blocks a key molecular signal that drives the malignant features of these tumors," said Amy Heimberger, M.D., associate professor in MD Anderson's Department of Neurosurgery and co-lead author of the paper. "If a patient's tumor expresses the target of this vaccine, she usually has only a 5 percent chance to live for two years."

All patients in the trial had the target variation, called epidermal growth factor receptor variant III (EGFRvIII), which occurs in about a third of glioblastomas and also is found in breast, lung and head and neck cancers. The flawed gene produces a protein that aids tumor development, migration and resistance to chemotherapy and radiation. It is not found in normal tissue.

Out of 11 tumor recurrences analyzed from vaccinated patients, the EGFRvIII cells were completely gone in nine, indicating that the vaccine had done its job eliminating the most aggressive cells, said co-lead author John Sampson, M.D., Ph.D., professor of Neurosurgery at Duke.

Other findings hint at the vaccine's likely effectiveness against EGFRvIII. Of six patients who had an immune response to the vaccine as indicated by blood tests, overall survival was 47.7 months compared with 22.8 months for those lacking a response. Median survival had not been reached after 50 months among three patients who had a T cell response to the vaccine.

However, the limited size of the sample calls for cautious interpretation of these results, Heimberger said. The next step for the vaccine, known as CDX-110, is a large phase III clinical trial, Heimberger said, which is in the planning stage.

The EGFRvIII variant was co-discovered by Bert Vogelstein, M.D., and Albert Wong, M.D., at Johns Hopkins University and Darrell Bigner, M.D., Ph.D., director of the brain tumor center at Duke and corresponding author of the JCO paper.

Glioblastomas have other molecular drivers, so tumors come back, which the authors say points to a need to develop vaccines that address more than one target.

Heimberger sees the addition of vaccines to glioblastoma treatment as one more way to convert the deadly tumors more of a chronic disease. Developments in recent years, including approval of the chemotherapy drug temozolomide, have extended expected survival from around seven months to 14.


'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-792-0661
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert  

Related medicine news :

1. Vaccine May Prevent TB in People With HIV
2. Vaccine Not Fail-Safe in Ongoing Mumps Outbreak
3. New strategy produces promising advance in cancer vaccines
4. Screens, Vaccine for HPV Less Beneficial in Older Women
5. New Technology Could Widen Reach of Vaccines
6. Texas-based consortium announces groundbreaking vaccine research program
7. The Coalition for Vaccine Safety Calls for Congressional Hearings on Federal Agencies Failure to Provide Adequate Safety Research
8. Possible vaccine for mesothelioma proven safe
9. Groundbreaking research to find vaccine for hepatitis C
10. Vaccine for Asbestos-Related Cancer Looks Safe
11. CDC Awards Abt Associates Additional Contracts to Evaluate Effectiveness of H1N1 Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Vaccine extends glioblastoma patients' survival in phase II trial
(Date:4/29/2016)... ... April 29, 2016 , ... A new study by ... congenital diaphragmatic hernia have better survival rates if surgery is performed early. Approximately ... where the diaphragm fails to form completely, letting abdominal organs into the chest ...
(Date:4/29/2016)... ... April 29, 2016 , ... The ... (CCA), is pleased to announce the launch of the GFCP Scoop ... and more. The purpose of the GFCP Scoop site is to ...
(Date:4/29/2016)... ... 29, 2016 , ... For those who skip meals occasionally (which is pretty ... among the many new lifestyle diet tips offered by nutritionists Pam Bonney and Priya ... Water® radio show. Bonny and Lawrence noted that because proper nutrition, including water, provides ...
(Date:4/29/2016)... Beach, CA (PRWEB) , ... April 29, 2016 , ... ... Jane L. Frederick, Dr. Sanaz Ghazal, and Dr. Daniel A. Potter -- are proud ... Society for Assisted Reproductive Technology (SART). In April, SART published the latest ...
(Date:4/29/2016)... ... April 29, 2016 , ... Coalition Duchenne, a ... and funding for Duchenne research, participated in the April 25 U.S. Food and ... Duchenne drug eteplirsen. The meeting at the Marriott Conference Center in Hyattsville, Maryland ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016 ... consumer insights on healthcare, announced today that it has ... report Cool Vendor in Life Sciences, 2016, ... 15, 2016.  The report focuses on life-science- oriented analytics, ... insight from patients and doctors, confirm medication ingestion, and ...
(Date:4/28/2016)... , April 28, 2016  ValGenesis, Inc., ... Management Solutions (VLMS) today announced that a ... for sufferers of chronic kidney failure has ... manage their corporate validation process. The global ... software solution to manage their validation processes ...
(Date:4/27/2016)... , le 27 Avril 2016 ... a progressé de +5% sur le trimestre, soutenu ... de consommables  Croissance de +16% des ... Mauna Kea Technologies (Euronext : MKEA, FR0010609263 ; ... confocale laser, annonce aujourd,hui son chiffre d,affaires pour ...
Breaking Medicine Technology: